Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

HHS vs CRESY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRESY Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

CRESY Overall Winner 6-Pillar Tally: HHS 1 – 4 CRESY (1 Tie) Matrix Metrics: HHS 4 – 6 CRESY

As of Nov 16, 2026, Cresud SA (CRESY) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HHS carries a Unified Composite Score of 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin), whereas CRESY carries 54.6/100 (HOLD) at $9.14 (60.1x Forward P/E, 19.3% operating margin).

  • Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. CRESY 54.6/100 HOLD), CRESY captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (19.3% vs. -3.2% operating margin) and revenue trajectory (+20.4% vs. -1.7% YoY).
  • Technical & Structure Timing Caution: HHS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.2); meanwhile CRESY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HHS vs CRESY
HHS US Equity
Harte Hanks, Inc.
Services-Direct Mail Advertising Services
$3.84
-4.24% 1D
Market Cap $30.0M
TTM Revenue $155M
Forward P/E 14.3x
Beta / 30D Vol 0.49β · 46% Vol
Unified Composite Score
61.8 / 100 BUY
Tech 76.0 Fund 61.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 38.2 · SMA20: $3.95 · SMA50: $4.26
CRESY NASDAQ Head-to-Head Winner
Cresud SA
Real Estate
$9.14
-6.16% 1D
Market Cap $650.9M
TTM Revenue $1.15B
Forward P/E 60.1x
Beta / 30D Vol 0.81β · 58% Vol
Unified Composite Score
54.6 / 100 HOLD
Tech 75.0 Fund 55.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 37
RSI-14: 36.6 · SMA20: $10.07 · SMA50: $11.20

6-Pillar Scorecard Institutional Category Breakdown (HHS 1 – 4 CRESY)

Columns: Metric · HHS · CRESY
1. Valuation Multiples HHS
Forward P/E 14.3x 60.1x
Trailing P/E 14.3x 5.9x
PEG Ratio 1.19x N/M
EV / Revenue 0.3x 0.6x
2. Growth & Scale CRESY
Revenue Growth (YoY) -1.7% +20.4%
Earnings Growth (YoY) -90.3% -93.6%
TTM Revenue (USD) $155M $1.15B
Market Cap $30.0M $650.9M
3. Profitability & Quality CRESY
Gross Margin 16.1% 42.1%
Operating Margin -3.2% 19.3%
Net Profit Margin -3.7% 9.6%
Return on Equity (ROE) -30.4% 8.6%
4. Balance Sheet & Cash Flow CRESY
Cash Generation (TTM) -$4.5M $236M EBITDA
Cash Flow Margin -2.9% 20.6% EBITDA Mgn
Net Cash / Leverage $17M Net Debt (1.10x D/E) $14.10 Book/Sh · 8.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 74.0% (100th %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CRESY
OpEx & R&D Intensity 19.3% of Rev ($30M) 22.8% of Rev ($262M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Conglomerates Operator Conglomerates Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HHS (4) vs CRESY (6)
Institutional Metric HHS CRESY Criterion Row Edge
Market Capitalization
Scale
$30.0M $650.9M Larger Scale CRESY
Trailing P/E Ratio
Valuation
14.3x 5.9x Lower Multiple CRESY
Forward P/E Ratio
Valuation
14.3x 60.1x Lower Multiple HHS
Revenue Growth (YoY)
Growth
-1.7% +20.4% Higher Growth CRESY
Operating Margin (TTM)
Profitability
-3.2% 19.3% Higher Margin CRESY
Net Profit Margin
Profitability
-3.7% 9.6% Higher Margin CRESY
Return on Equity (ROE)
Capital Efficiency
-30.4% 8.6% Higher ROE CRESY
52-Week Range Position
Momentum
69% ($2–$5) 7% ($9–$14) Stronger Trend HHS
Beta / 30D Volatility
Risk Regime
0.49β · 46% Vol 0.81β · 58% Vol Lower Realized Risk HHS
Unified Institutional Score
Composite Signal
61.8 / 100 (BUY) 54.6 / 100 (HOLD) Higher Composite HHS
Trailing 12M Revenue (USD)
Operating Scale
$155M $1.15B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.1% 42.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.19x PEG · 0.3x EV/Rev N/M PEG · 0.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$4.5M ($17M Net Debt (1.10x D/E)) $236M EBITDA ($14.10 Book/Sh · 8.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HHS +10.17 pp
HHS: -10.49% · CRESY: -20.66%
3M Horizon HHS +8.1 pp
HHS: -3.76% · CRESY: -11.86%
6M Horizon HHS +54.2 pp
HHS: +36.17% · CRESY: -18.03%
1Y Horizon HHS +55.26 pp
HHS: +34.74% · CRESY: -20.52%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HHS vs CRESY. Trailing 12-month operating profitability (HHS -3.2% vs CRESY 19.3%) and valuation multiples (HHS 14.3x vs CRESY 60.1x Forward P/E) are benchmarked directly in Pillar 4 below.

HHS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$155M
Gross Margin16.1%
Op. Margin-3.2%
ROE / Fwd P/E-30.4% · 14.3x
CRESY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.15B
Gross Margin42.1%
Op. Margin19.3%
ROE / Fwd P/E8.6% · 60.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HHS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HHS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRESY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 74.0%
IV Percentile 100th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CRESY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HHS Moat Profile Cyclical / Execution-Driven Positioning
Conglomerates Operator
Competes within the Conglomerates value chain with $30.0M market capitalization and -3.2% operating margin.
OpEx & R&D Reinvestment 19.3% of Rev ($30M)
90D Engineering Disclosures 0 Published
CRESY Moat Profile Scale & Operating Efficiency Moat
Conglomerates Operator
Competes within the Conglomerates value chain with $650.9M market capitalization and 19.3% operating margin.
OpEx & R&D Reinvestment 22.8% of Rev ($262M)
90D Engineering Disclosures 0 Published

Investor FAQ HHS vs CRESY Key Questions & Quantitative Answers

As of Nov 16, 2026, Cresud SA (CRESY) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HHS carries a Unified Composite Score of 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin), whereas CRESY carries 54.6/100 (HOLD) at $9.14 (60.1x Forward P/E, 19.3% operating margin). Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. CRESY 54.6/100 HOLD), CRESY captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (19.3% vs. -3.2% operating margin) and revenue trajectory (+20.4% vs. -1.7% YoY). Technical & Structure Timing Caution: HHS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.2); meanwhile CRESY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRESY leads the Growth & Scale pillar: HHS posts -1.7% YoY revenue growth and -90.3% YoY earnings growth on $155M TTM revenue (16.1% gross margin, -3.2% operating margin), compared with CRESY at +20.4% YoY revenue growth and -93.6% YoY earnings growth on $1.15B TTM revenue (42.1% gross margin, 19.3% operating margin). On trailing 12-month operating scale, HHS generates $155M in USD-normalized revenue versus $1.15B for CRESY. In operating R&D and SG&A reinvestment, HHS deploys 19.3% of Rev ($30M) (0 90-day corporate R&D disclosures) versus 22.8% of Rev ($262M) (0 disclosures) for CRESY.

HHS screens cheaper on headline valuation multiples. HHS trades at 14.3x Forward P/E, 14.3x Trailing P/E, 1.19x PEG, and 0.3x EV/Revenue (-2.9% FCF margin), whereas CRESY trades at 60.1x Forward P/E, 5.9x Trailing P/E, N/M PEG, and 0.6x EV/Revenue (20.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HHS (-30.4% ROE) versus CRESY (8.6% ROE) capital efficiency.

In options market volatility and institutional positioning, HHS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 46% Vol realized risk). By comparison, CRESY carries 74.0% implied volatility (100th %ile, Extreme (>80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.